

**Alameda Alliance for Health**  
1240 South Loop Road  
Alameda, CA 94502

Location: Microsoft Teams  
Meeting ID: 273 947 871 116  
Password: Za6J3N

**IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS**

STATE OR LOCAL OFFICIALS CONTINUE TO IMPOSE OR RECOMMEND MEASURES TO PROMOTE SOCIAL DISTANCING. AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO “ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE” 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT [bochoa@alamedaalliance.org](mailto:bochoa@alamedaalliance.org). YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: [Microsoft Teams Meeting](#) OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MAY SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE OR PROVIDE COMMENT [DURING THE MEETING AT THE END OF EACH TOPIC](#).

**PLEASE NOTE:** THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. DURING EACH AGENDA ITEM, YOU WILL BE PROVIDED A REASONABLE AMOUNT OF TIME TO PROVIDE PUBLIC COMMENT. THE COMMITTEE WOULD APPRECIATE, HOWEVER, IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING.

## AGENDA

ITEM VOTE	DESCRIPTION	TIME
I)	<b>Call to order</b> <i>Steve O'Brien, MD, Chief Medical Officer – Alameda Alliance</i> <ul style="list-style-type: none"> <li>Agenda Overview</li> </ul>	2 min -
II)	<b>Informational Updates</b> <i>Steve O'Brien, MD, Chief Medical Officer – Alameda Alliance</i> <i>Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> <li>CalAIM Updates (ECM, CS x 12, TCS, LTC, ICF-DD, BH/ABA)</li> <li>CEO &amp; COO Transition</li> <li>DHCS Audit results</li> <li>PAD Updates</li> <li>Medi-Cal Rx MCDAC Drugs (See Next Page)</li> </ul>	15 min -
III)	<b>Pharmacy Utilization Reports (Quarter 1, 2023)</b> <i>Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> <li>Top 50 Drugs by Cost</li> <li>Top 50 PA Reviewed Drugs</li> </ul>	2 min -

MCDAC Drug	Indication	CDL Status	Recommendation Based on - Safety, Efficacy, Essential Need, Misuse Potential, etc.	Previous MCAL Status
Amjevita (adalimumab-atto) 20mg/0.4ml, 40mg/0.8ml pre-filled syringe and 40mg/0.8ml pre-filled sureclick autoinjector	Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylosis, Crohn's Disease, Ulcerative Colitis and Plaque Psoriasis	F-PA	Keep F-PA	N/A, F-PA in GC
Austedo (deutetrabenazine) 6mg, 9mg and 12mg tablets; Austedo XR (deutetrabenazine) 6mg, 12mg and 24mg tablets	Tardive Dyskinesia, Chorea associated Huntington's Disease	F (Austedo) and F-PA (Austedo XR)	Keep F-PA	NF

**ADJOURN TO CLOSED SESSION** (Pursuant to California Government Code Title 5, §54954.5(h))

**Discussion will Concern:** Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes

**Estimated Date of Public Disclosure: 6/20/2023** (formulary changes only; no trade secrets will be disclosed)

**IV) E-Voting Material/Consent Agenda**

**The following items have been sent to the voting committee for review via E-voting**

Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance

Benita Ochoa, CPhT – Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

Monographs/Class Reviews	Changes
Opioids and Opioid Combinations Class Review	• No change
Contraceptive Foams, Devices Class Review	• No change
Diuretics Class Review	• No change
Gaucher Disease Class Review	• No change
Sucraid Monograph	• No change
Ridaura Monograph	• No change
Provenge Monograph	• No change
Medication Request Guidelines	Changes
Short acting opioids (part of opioid class review)	• Policy name update
Long acting opioids (part of opioid class review)	• Policy name update
Butorphanol (part of opioid class review)	• No change
Diuretics (part of diuretics class review)	• No change
Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)	• Add new medication Briumvi to policy
Pregabalin (Lyrica and Lyrica CR)	• Update Lyrica CR brand/generic status
vigabatrin (Sabril)	• Update criteria statement to align with criteria

10 min EV

Hereditary Angioedema (HAE)	<ul style="list-style-type: none"> <li>Update criteria statement to align with criteria</li> </ul>
Topiramate (Topamax) sprinkles	<ul style="list-style-type: none"> <li>Minor wording update</li> </ul>
Emflaza (deflazacort)	<ul style="list-style-type: none"> <li>Minor wording update</li> </ul>
febuxostat (Uloric)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Formulary, step therapy required *For drugs without specific criteria	<ul style="list-style-type: none"> <li>No change</li> </ul>
Non-formulary and prior authorization required oral liquid formulations	<ul style="list-style-type: none"> <li>No change</li> </ul>
Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention	<ul style="list-style-type: none"> <li>No change</li> </ul>
Lamotrigine ER	<ul style="list-style-type: none"> <li>No change</li> </ul>
Levalbuterol (Xopenex/Xopenex HFA)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Lidocaine Patch	<ul style="list-style-type: none"> <li>No change</li> </ul>
Potassium-removing agents	<ul style="list-style-type: none"> <li>No change</li> </ul>
Fenofibrates	<ul style="list-style-type: none"> <li>No change</li> </ul>
Nutritional formulas, infant formulas (STC C5F C5C)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Serotonin Receptor Agonists (Triptans)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Rufinamide (Banzel)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Tiagabine (Gabitril)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Phosphate Binders	<ul style="list-style-type: none"> <li>No change</li> </ul>
Movement Disorders	<ul style="list-style-type: none"> <li>No change</li> </ul>
Aptiom (eslicarbazepine)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Alprazolam (Xanax)	<ul style="list-style-type: none"> <li>No change</li> </ul>
Rectiv (nitroglycerin) ointment	<ul style="list-style-type: none"> <li>No change</li> </ul>
Acute Migraine Treatments	<ul style="list-style-type: none"> <li>No change</li> </ul>
Palforzia	<ul style="list-style-type: none"> <li>No change</li> </ul>
Lupkynis	<ul style="list-style-type: none"> <li>No change</li> </ul>
<b>Physician Administered Drug (PAD) Guidelines</b>	<b>Changes</b>
Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)	<ul style="list-style-type: none"> <li>Add new medication Briumvi to policy</li> </ul>
Naglazyme	<ul style="list-style-type: none"> <li>No change</li> </ul>
Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention	<ul style="list-style-type: none"> <li>No change</li> </ul>

<b>Interim Formulary Updates</b>	
<ul style="list-style-type: none"> <li>See p. 156 in packet</li> </ul>	
<b>Pharmacy Policy &amp; Procedure Updates</b>	
<ul style="list-style-type: none"> <li>RX-002 – PA Review Process</li> </ul>	<ul style="list-style-type: none"> <li>Update TAT section</li> </ul>
<ul style="list-style-type: none"> <li>RX-003 - Exception Review Process</li> </ul>	<ul style="list-style-type: none"> <li>Medical necessity NOA language update</li> </ul>
<ul style="list-style-type: none"> <li>RX-005 - P&amp;T Committee Roles</li> </ul>	<ul style="list-style-type: none"> <li>Stipend language update</li> </ul>
<ul style="list-style-type: none"> <li>RX-013 – Physician Facility-Administered Drugs (PAD) Prior Authorization Review Process</li> </ul>	<ul style="list-style-type: none"> <li>Updates with 6/19/2023 go-live</li> </ul>
<b>ED Oversight</b>	
<ul style="list-style-type: none"> <li>No updates</li> </ul>	
<b>90 Day Maintenance List updates</b>	
<ul style="list-style-type: none"> <li>No updates</li> </ul>	
<b>P&amp;T Meeting Minutes</b>	
<ul style="list-style-type: none"> <li>P&amp;T Meeting Minutes Q1 March 28, 2023</li> </ul>	

**V) New Business**

*Helen Lee, PharmD, MBA, Senior Pharmacy Pharmacist – Alameda Alliance*  
*Timothy Tong, PharmD, Pharmacist – Alameda Alliance*  
*Natalee Felten, PharmD, Pharmacist – PerformRx*

- AAH UM Medication PA List & Infusion Codes
- Radicava ORG MRG, Radicava injection PAD - new

**VI) Class Reviews, Monographs, and Recommendations**

*Natalee Felten, PharmD, Pharmacist – PerformRx*

- Filspari Monograph + new MRG
- Daybue Monograph + new MRG
- Joenja Monograph + new MRG
- Skyclarys Monograph + new MRG
- Attention Deficit Hyperactivity Disorder (ADHD) Class Review

**VII) Medication Request Guidelines**

*Rahel Negash, PharmD, Pharmacist, Pharmacy Supervisor – Alameda Alliance*

- Gonadotropin Releasing Hormone Antagonist Combination Products
- Orilissa (elagolix) - RETIRE
- Sleep Disorder Therapy
- Cholinesterase Inhibitors
- Daliresp (roflumilast)
- Injectable Atypical Antipsychotic Medications
- Hepatitis C Medications
- Hemlibra (emicizumab-kxwh)
- Lipotropics
- Sedative Hypnotics
- Epidiolex (cannabidiol)
- Agents for Atopic Dermatitis

45 min **V**

**VIII) Physician Administered Drug (PAD) Policies**

*Natalee Felten, PharmD, Pharmacist – PerformRx*

1. Complement Inhibitors
2. Anti-CD19 CAR-T Immunotherapies
3. B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy
4. SMN2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy (SMA)

10 min V

**IX) Informational Updates on New Developments in Pharmacy**

*Natalee Felten, PharmD, Pharmacist – PerformRx*

- New Product Review

2 min -

**X) Old Business**

*Natalee Felten, PharmD, Pharmacist – PerformRx*

- None

2 min -

**RECONVENE IN OPEN SESSION**

**XI) Public Comment**

**XII) Adjournment**

- P&T Committee Member Forms

**ACTION / FOLLOW-UP ITEMS**

ITEM	DUE DATE	RESPONSIBLE

**FUTURE P&T MEETINGS**

NEXT MEETING	2023 P&T MEETINGS
September 26 2023	December 19 2023

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

**Note:** Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or [hlee@alamedaalliance.org](mailto:hlee@alamedaalliance.org) at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.